Mitigation of cutaneous injury with IL-12
View Patent ↗The present application relates to treatment of cutaneous wounds using IL-12. The methods of the invention result in improved wound closure. The methods comprise treating cutaneous wounds using topical, subcutaneous, and/or intramuscular administration of IL-12.
1. A method for treating a cutaneous wound in a subject, comprising subcutaneously administering a therapeutically effective amount of Interleukin-12 (IL-12) to a patient with a cutaneous wound, wherein the cutaneous wound is due to a burn, physical trauma, surgical trauma or an underlying factor slowing the wound closure.
2. The method of claim 1 , wherein the subject is human.
3. The method of claim 1 , further comprising a second administration of IL-12, wherein the second administration of IL-12 is administered subcutaneously or topically.
4. The method of claim 3 , wherein the IL-12 is administered topically in a dosage of from about 1 ng/mL up to about 10 μg/mL.
5. The method of claim 3 , wherein the IL-12 is administered topically in a dosage of from about 10 ng/mL up to about 5 μg/mL.
6. The method of claim 3 , wherein the IL-12 is administered topically at a dosage of about 100 ng mL.
7. The method of claim 3 , wherein the topically administered IL-12 is administered in conjunction with acellular or cellular dermal matrices.
8. The method of claim 3 , wherein the topically administered IL-12 is emulsified in a gel matrix.
9. The method of claim 8 , wherein the gel matrix is isotonic 4% carboxymethylcellulose.
10. The method of claim 1 , wherein the IL-12 is administered subcutaneously in a dosage of from about 10 ng/kg to about 500 ng/kg.
11. The method of claim 10 , wherein the IL-12 is administered subcutaneously in a dosage of about 100-200 ng/kg.
12. The method of claim 1 , wherein the wound is an open wound.
13. The method of claim 12 , wherein administration of IL-12 results in at least about a 5% increase in wound healing as measured by wound closure over a specified time period, as compared to wound closure observed in the absence of IL-12 administration.
14. The method of claim 12 , wherein administration of IL-12 results in at least about a 20% increase in wound healing as measured by wound closure over a specified time period, as compared to wound closure observed in the absence of IL-12 administration.
15. The method of claim 12 wherein administration of IL-12 results in at least about a 50% increase in wound healing as measured by wound closure over a specified time period, as compared to wound closure observed in the absence of IL-12 administration.
16. The method of claim 12 , wherein administration of IL-12 results in at least about a 75% increase in wound healing as measured by wound closure over a specified time period, as compared to wound closure observed in the absence of IL-12 administration.
17. The method of claim 12 , wherein administration of IL-12 results in at least about a 95% increase in wound healing as measured by wound closure over a specified time period, as compared to wound closure observed in the absence of IL-12 administration.
18. The method of claim 1 , wherein the burn was caused by exposure to radiation, which results in a cutaneous wound.
19. The method of claim 18 , wherein the IL-12 is administered from about 1 hour up to about 120 hours following exposure to radiation resulting in a cutaneous wound.
20. The method of claim 18 , wherein the radiation is gamma radiation.
21. The method of claim 1 , wherein the subject is a member of a patient population characterized by an impediment to normal cutaneous wound healing.
22. The method of claim 1 , wherein the subject is diabetic.
23. The method of claim 1 , wherein the burn is a second, third or fourth degree burn.
24. The method of claim 1 , wherein the surgical trauma is present at a surgical site.
25. The method of claim 24 , wherein administration of IL-12 results in a decrease in the incidence of infection at the surgical site.
26. The method of claim 1 , wherein the IL-12 is administered in conjunction with a skin graft.
27. The method of claim 1 , wherein the wound is a full-thickness wound or a partial thickness wound.
28. The method of claim 1 , wherein the subject is elderly.
29. The method of claim 28 , wherein administration of IL-12 results in a decrease in the incidence of infection of a diabetic ulcer.